[go: up one dir, main page]

FI117387B - Pyranonföreningar, som är användbara vid behandling av retrovirusinfertioner - Google Patents

Pyranonföreningar, som är användbara vid behandling av retrovirusinfertioner Download PDF

Info

Publication number
FI117387B
FI117387B FI964441A FI964441A FI117387B FI 117387 B FI117387 B FI 117387B FI 964441 A FI964441 A FI 964441A FI 964441 A FI964441 A FI 964441A FI 117387 B FI117387 B FI 117387B
Authority
FI
Finland
Prior art keywords
formula
propyl
compound
hydroxy
phenyl
Prior art date
Application number
FI964441A
Other languages
English (en)
Finnish (fi)
Other versions
FI964441A0 (sv
FI964441L (sv
Inventor
Gordon L Bundy
Suvit Thaisrivongs
Paul Adrian Aristoff
Joseph Walter Strohbach
Steven Ronald Turner
Louis L Skaletzki
Ronald B Gammill
Paul D Johnson
Harvey Irving Skulnick
Ruben A Tommasi
George P Luke
Karen Rene Romines
Theresa M Schwarz
David John Anderson
Joel Morris
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI964441A0 publication Critical patent/FI964441A0/sv
Publication of FI964441L publication Critical patent/FI964441L/sv
Application granted granted Critical
Publication of FI117387B publication Critical patent/FI117387B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (12)

1. Förening med farmein OH R3 to r2 5 nh-so2-r4 väri Ri och R2 oberoende av varandra är valda bland: g) n-propyl, h) het-S02NH-(CH2)2-, 10 i) 2-metylpropyl och d) fenyl-(CH2)2-, R3 är cyklopropyl, etyl eller t-butyl, R4 är het eller cyanofenyl, och het är 4-imidazolyl, 2-pyridinyl eller 8-quinolinyl, av vilka envar möjligen är 15 substituerad med CH3, CN, CF3, NH2 eller CONH2, *;··: eller ett farmaceutiskt acceptabelt sait därav. • 1·
2. Förening enligt patentkrav 1, väri *7:\ R1 är n-propyl eller 2-fenyletyl, 7". 20 R2 är n-propyl eller 2-fenyletyl, R3 är etyl eller t-butyl och ** * R4 är 4-imidazolyl eller 2-pyridinyl substituerad med CH3, CN eller CF3.
3. Förening enligt patentkrav 1 som är 5-amino-N-[3(R eller S)-(1-[5,6-dihydro-4-25 hydroxi-2-oxo-6(R eller S)-(2-fenyletyl)-6-propyl-2H-pyran-3-yl]propyl)fenyl]-2-pyri- 7. dinsulfonamid. ψ » · f ♦ ♦ · #r‘
4. Förening enligt patentkrav 1 som är N-[3(R eller S)-(1-[6,6-bis(2-fenyletyl)-5,6- « * L: : dihydro-4-hydroxi-2-oxo-2H-pyran-3-yl]propyl)fenyl]-5-cyano-2-pyridinsulfonamid. *««
5. Förening enligt patentkrav 1 som är N-[3-{1-(4-hydroxi*5,6-dihydro-2-oxo-6,6-dipropyl^H-pyran-S-ylJpropylJfenyll-S-karbamoylpyridin^-sulfonamid. 30 1 1 7387 236
6. Förening enligt patentkrav 1 som är N-[3-{1(R eller S)-(4-hydroxi-5,6-dihydro-2-oxo-6(R eller S)-(2-fenyletyl)-6-propyl-2H-pyran-3-yl)propyl}fenyl]-5-cyanopyridin- 2-sulfonamid. 5
7. Förening enligt patentkrav 1 som är N-[3-{1(R eller S)-(4-hydroxi-5,6-dihydro-2- oxo-6,6-dipropyl-2H-pyran-3-yl)-propyl}fenyl]-5-cyanopyridin-2-sulfonamid.
8. Förening enligt patentkrav 1 som är N-[3-{1(R eller S)-(4-hydroxi-5,6-dihydro-2-oxo-6,6-dipropyl-2H-pyran-3-yl)-propyl}fenyl]-5-aminopyridin-2-sulfonam id. 10
9. Förening enligt patentkrav 1 som är (3R eller S)-N-[3-[1-(5,6-dihydro-4-hydroxi-2-oxo-6,6-dipropyl-2H-pyran-3-yl)propyl]fenyl]-5-(trifluorometyl)-2-pyri-dinsulfonamid. 15
10. Förening enligt patentkrav 1 som är N-[3(R eller S)-[1-[5,6-dihydro-4-hydroxi-2- oxo-6(R eller S)-(2-fenyletyl)-6-propyl-2H-pyran-3-yl]propyl]fenyl]-5-trifluorometyl-2-pyridinsulfonamid.
11. Förening enligt patentkrav 1 som är N-[3(R eller S)-[1-(5,6-dihydro-4-hydroxi-2-20 oxo-6(R eller S)-(2-fenyletyl)-6-propyl-2H-pyran-3-yl)-2,2-dimetylpropyl]fenyl]-1- metyl-1 H-imidazol-4-sulfonamid. * *
12. Förening enligt patentkrav 1 som är 5-tritluorometyl-N-[3(R)-[1-[5,6-dihydro-4- ·:> hydroxi-2-oxo-6(R)-(2-fenyletyl)-6(R)-n-propyl-2H-pyran-3-yl]-propyl]-fenyl]-2-pyri- ·**· 25 dinsulfonamid eller ett farmaceutiskt acceptabelt sait därav. ·««· « · * • i * i«« »44 9 m 9 • 9 9 • 4 • 4 4 • 4 * • · 4 1·« • 4 • * • »4 • • 9 9 9 9 • · I 999 9 M» • 4 • 4 *·« • « 4 • · 9 9 9 9 »»I i i 99 9 9 • 9 444
FI964441A 1994-05-06 1996-11-05 Pyranonföreningar, som är användbara vid behandling av retrovirusinfertioner FI117387B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US23881794A 1994-05-06 1994-05-06
US23881794 1994-05-06
US34936194A 1994-12-02 1994-12-02
US34936194 1994-12-02
US9505219 1995-05-04
PCT/US1995/005219 WO1995030670A2 (en) 1994-05-06 1995-05-04 Pyranone compounds useful to treat retroviral infections

Publications (3)

Publication Number Publication Date
FI964441A0 FI964441A0 (sv) 1996-11-05
FI964441L FI964441L (sv) 1996-11-05
FI117387B true FI117387B (sv) 2006-09-29

Family

ID=26931995

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964441A FI117387B (sv) 1994-05-06 1996-11-05 Pyranonföreningar, som är användbara vid behandling av retrovirusinfertioner

Country Status (33)

Country Link
US (2) US5852195A (sv)
EP (1) EP0758327B1 (sv)
JP (1) JP3883206B2 (sv)
KR (1) KR100445929B1 (sv)
CN (2) CN1329378C (sv)
AT (1) ATE236894T1 (sv)
AU (2) AU701965B2 (sv)
BR (1) BR9507615A (sv)
CA (2) CA2560489C (sv)
CO (1) CO4810313A1 (sv)
CZ (1) CZ296515B6 (sv)
DE (2) DE69530294T2 (sv)
DK (1) DK0758327T3 (sv)
ES (1) ES2192201T3 (sv)
FI (1) FI117387B (sv)
FR (1) FR05C0047I2 (sv)
HK (2) HK1066796A1 (sv)
HU (1) HU228057B1 (sv)
IL (3) IL129871A (sv)
LU (1) LU91220I2 (sv)
MX (1) MX9605391A (sv)
MY (2) MY127701A (sv)
NL (1) NL300216I2 (sv)
NO (2) NO315799B1 (sv)
NZ (1) NZ285510A (sv)
PE (1) PE23196A1 (sv)
PL (1) PL190540B1 (sv)
PT (1) PT758327E (sv)
RU (1) RU2139284C1 (sv)
SI (1) SI0758327T1 (sv)
SK (1) SK284407B6 (sv)
TW (1) TW504507B (sv)
WO (1) WO1995030670A2 (sv)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP0909184B1 (en) * 1996-07-03 2003-09-17 PHARMACIA & UPJOHN COMPANY Targeted drug delivery using sulfonamide derivatives
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
RU2202346C2 (ru) * 1997-07-29 2003-04-20 Фармация Энд Апджон Компани Фармацевтическая композиция для кислотных липофильных соединений в форме самоэмульгирующейся композиции
ATE215370T1 (de) * 1997-07-29 2002-04-15 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
RU2211021C2 (ru) * 1997-07-29 2003-08-27 Фармация Энд Апджон Компани Фармацевтическая самоэмульгирующая композиция и ее носитель для липофильных фармацевтически активных агентов
ATE266654T1 (de) 1997-09-11 2004-05-15 Upjohn Co Verfahren zur herstellung von als protease inhibitoren wervollen 4-hydroxy-2-oxo-pyran- derivaten
JP3610014B2 (ja) 1999-03-18 2005-01-12 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 不斉水素化のための改良された製法
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
CZ304118B6 (cs) 2000-01-19 2013-11-06 Abbott Laboratories Farmaceutická kompozice
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
GB2401606B (en) * 2002-02-25 2005-08-31 Kudos Pharm Ltd Pyranones useful as ATM inhibitors
ES2268394T3 (es) * 2002-04-01 2007-03-16 Pfizer Inc. Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
IL161586A (en) * 2004-04-22 2015-02-26 Rafael Advanced Defense Sys Irreplaceable energetic material and reactive shielding that uses it
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
US20060135563A1 (en) * 2004-12-01 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and SCH-417690
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
JP2008521898A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US20090062346A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched tipranavir
WO2009042093A1 (en) * 2007-09-25 2009-04-02 Merck & Co., Inc. Hiv protease inhibitors
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009114151A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
AU2010254415B2 (en) 2009-05-27 2013-07-04 Merck Sharp & Dohme Corp. HIV protease inhibitors
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
SI2442809T1 (sl) 2009-06-17 2017-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov gripe
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
US8772332B2 (en) * 2010-09-09 2014-07-08 Richard H. Ebright Arylpropionyl-alpha-pyrone antibacterial agents
US10800725B2 (en) 2010-09-09 2020-10-13 Richard H. Ebright Arylpropionyl-triketone antibacterial agents
WO2012037508A2 (en) 2010-09-17 2012-03-22 Rutgers, The State University Of New Jersey Antibacterial agents: high-potency myxopyronin derivatives
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
WO2012083117A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
US9517994B2 (en) 2012-01-05 2016-12-13 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
AU2013315833A1 (en) 2012-09-11 2015-03-05 Merck Canada Inc. HIV protease inhibitors
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
MX382171B (es) 2013-11-13 2025-03-13 Vertex Pharmaceuticals Incorporated Inhibidores de replicacion del virus de influenza.
AU2014348752C1 (en) 2013-11-13 2019-11-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9994587B2 (en) 2014-03-06 2018-06-12 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2017100645A2 (en) 2015-12-10 2017-06-15 Rutgers, The State University Of New Jersey Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
US11993590B2 (en) * 2016-12-04 2024-05-28 712 North Inc. Pyranone compounds useful to modulate OMA1 protease
WO2019160875A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: soluble salts and aqueous formulations of pyronins
WO2019160873A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: o-alkyl-deuterated pyronins
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
CN110551090B (zh) * 2019-10-21 2021-06-18 扬州工业职业技术学院 一种超声波提取中药狗脊中抗肿瘤活性成分的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2024130166A2 (en) * 2022-12-16 2024-06-20 Denali Therapeutics Inc. Compounds, compositions, and methods

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB193507A (en) 1921-11-25 1923-02-26 English Electric Co Ltd Improvements in and connected with hydraulic impulse turbines
NL80964C (sv) * 1952-03-08
NL83407C (sv) * 1952-05-16
US2723277A (en) * 1952-08-26 1955-11-08 Hoffmann La Roche Malonic acid derivatives and process for the manufacture thereof
US2872457A (en) * 1956-04-19 1959-02-03 Wisconsin Alumni Res Found Process for the preparation of 4-hydroxycoumarin derivatives
GB836740A (en) * 1956-04-25 1960-06-09 Bayer Ag Coumarin derivatives and their production
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1463767A (fr) * 1963-04-03 1966-07-22 Clin Byla Ets Dérivés de la coumarine et leur préparation
BE674997A (sv) * 1965-01-13 1966-07-12
FR1559595A (sv) * 1966-12-13 1969-03-14
US3489774A (en) * 1967-04-24 1970-01-13 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno) propionyl)-coumarin products
US3493586A (en) * 1969-01-23 1970-02-03 Dow Chemical Co 3-(beta-aryl-beta-(arylthio) (or arylseleno)-propionyl)pyrone products
JPS4823942B1 (sv) * 1969-02-14 1973-07-17
US3764693A (en) * 1969-11-21 1973-10-09 Lipha A rodenticidal compositions containing 4-hydroxy coumarins
US3835161A (en) * 1972-10-24 1974-09-10 Realisations Scient S E Res C 3-substituted-4-hydroxy-coumarins
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
NZ194557A (en) * 1979-08-17 1984-09-28 Merck & Co Inc Substituted pyranone derivatives;dihydroxy acids therefrom;pharmaceutical compositions
CA1171424A (en) * 1981-06-17 1984-07-24 Alvin K. Willard ( )-(4r, 6s) - (e)-6-[2-(4'fluro-3,3', 5-trimethyl- [l,l'-biphenyl]-2-yl)ethenyl]-3,4,5,6- tetrahydro-4-hydroxy-2h-pyran-2-one
JPS634652A (ja) * 1986-06-25 1988-01-09 Hitachi Ltd 半導体装置
AU1044088A (en) 1986-12-17 1988-07-15 Nippon Soda Co., Ltd. Heterocyclic compounds having triketo skeleton
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
EP0403535A1 (en) * 1988-03-01 1990-12-27 The Upjohn Company Coumarins to inhibit reverse transcriptase in humans
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
EP0494231A4 (en) * 1989-09-26 1992-09-16 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
CA2066644A1 (en) * 1989-10-27 1991-04-28 Robert L. Heinrikson Method for treating hiv and other retroviruses and compounds useful therefor
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
AU8612491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds
AU8448491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
JPH07110853B2 (ja) * 1990-09-07 1995-11-29 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
EP0578745A1 (en) * 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
AU2871592A (en) * 1991-10-11 1993-05-03 Du Pont Merck Pharmaceutical Company, The Cyclic ureas and analogues useful as retroviral protease inhibitiors
JP3070767B2 (ja) * 1991-10-22 2000-07-31 オクタマー，インコーポレイティド 抗腫瘍及び抗―レトロウィルス剤として有用なアデノシンジホスホリボースポリメラーゼ結合性ニトロソ芳香族化合物
DE4308451A1 (de) * 1992-09-10 1994-04-14 Bayer Ag 3-Aryl-pyron-Derivate
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections

Also Published As

Publication number Publication date
HU9603074D0 (en) 1997-01-28
AU718117B2 (en) 2000-04-06
KR100445929B1 (ko) 2005-09-30
IL129871A0 (en) 2000-02-29
CN1150424A (zh) 1997-05-21
HK1066796A1 (en) 2005-04-01
MY127701A (en) 2006-12-29
CA2560489A1 (en) 1995-11-16
MY149862A (en) 2013-10-31
NO2006003I1 (no) 2006-03-13
ATE236894T1 (de) 2003-04-15
PL317061A1 (en) 1997-03-03
PT758327E (pt) 2003-08-29
FR05C0047I2 (sv) 2007-10-19
SI0758327T1 (en) 2003-08-31
DE122006000014I1 (de) 2006-11-16
NZ285510A (en) 1998-03-25
EP0758327A1 (en) 1997-02-19
HK1084667A1 (en) 2006-08-04
CZ317296A3 (en) 1997-04-16
NO964676L (no) 1997-01-06
DE122006000014I2 (de) 2007-03-29
NL300216I1 (nl) 2006-04-03
US5852195A (en) 1998-12-22
AU2368699A (en) 1999-06-03
KR970702858A (ko) 1997-06-10
WO1995030670A3 (en) 1996-04-25
AU701965B2 (en) 1999-02-11
BR9507615A (pt) 1997-09-09
DK0758327T3 (da) 2003-07-28
MX9605391A (es) 1997-12-31
JP3883206B2 (ja) 2007-02-21
SK138496A3 (en) 1997-06-04
HU228057B1 (en) 2012-09-28
RU2139284C1 (ru) 1999-10-10
PE23196A1 (es) 1996-06-07
PL190540B1 (pl) 2005-12-30
CN1329378C (zh) 2007-08-01
CA2187523A1 (en) 1995-11-16
NO2006003I2 (no) 2008-10-20
DE69530294T2 (de) 2003-12-24
CA2560489C (en) 2010-01-12
IL113567A (en) 2003-05-29
NL300216I2 (nl) 2006-06-01
CN1154642C (zh) 2004-06-23
AU2462695A (en) 1995-11-29
FR05C0047I1 (sv) 2006-03-10
US6169181B1 (en) 2001-01-02
WO1995030670A2 (en) 1995-11-16
DE69530294D1 (de) 2003-05-15
IL129871A (en) 2003-11-23
NO315799B1 (no) 2003-10-27
CN1539825A (zh) 2004-10-27
ES2192201T3 (es) 2003-10-01
CO4810313A1 (es) 1999-06-30
CA2187523C (en) 2006-11-21
CZ296515B6 (cs) 2006-04-12
FI964441A0 (sv) 1996-11-05
EP0758327B1 (en) 2003-04-09
TW504507B (en) 2002-10-01
HUT77601A (hu) 1998-06-29
JPH09512821A (ja) 1997-12-22
LU91220I2 (fr) 2006-04-10
FI964441L (sv) 1996-11-05
SK284407B6 (sk) 2005-03-04
NO964676D0 (no) 1996-11-05

Similar Documents

Publication Publication Date Title
FI117387B (sv) Pyranonföreningar, som är användbara vid behandling av retrovirusinfertioner
EP0668860B1 (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
US5686486A (en) 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections
CN1749252B (zh) 用于治疗逆转录病毒感染的化合物

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117387

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: PHARMACIA & UPJOHN COMPANY LLC

Free format text: PHARMACIA & UPJOHN COMPANY LLC

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060015

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 297

Extension date: 20200504

MA Patent expired